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Background:  Shivering associated with spinal anesthesia is uncomfortable and may interfere with monitoring. 
The aim of this study is to evaluate the effect of ramosetron, a serotonin-3 receptor antagonist, on the prevention of 
shivering during spinal anesthesia.
Methods:  We enrolled 52 patients who were ASA I or II and who had undergone knee arthroscopy under spinal 
anesthesia.  Warmed (37
o) lactated Ringer’s solution was infused over 15 minutes before spinal anesthesia.  Patients 
were randomly allocated to a control group (group S, N = 26) or study group (group R, N = 26).  Spinal anesthesia was 
performed with a 25-G Quincke-type spinal needle between the lumbar 3-4 interspace with 2.2 ml 0.5% hyperbaric 
bupivacaine.  For patients allocated in groups S and R, 2 ml 0.9% saline and 0.3 mg ramosetron, respectively, was 
intravenously injected immediately before intrathecal injection at identical times.  Shivering and spinal block levels 
were assessed immediately after the completion of subarachnoid injection, as well as 5, 10, 15, 20, 25, 30, 60, and 120 
minutes after spinal anesthesia. Systolic and diastolic blood pressures, heart rate, and peripheral oxygen saturation 
were also recorded.  Core temperatures were measured by tympanic thermometer and recorded before and during 
spinal anesthesia at 30-minute intervals.
Results:  Shivering was observed in 2 patients in group R and 9 patients in group S (P = 0.038, odds ratio = 6.14, 95% C.I. 
= 1.08-65.5). The difference in core temperature between the groups was not significant. 
Conclusions:  Compared to control, ramosetron is an effective way to prevent shivering during spinal anesthesia.   
(Korean J Anesthesiol 2010; 58: 256-259)
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Introduction
    Shivering is a relatively common complication in regional 
anesthesia. Regional anesthesia significantly impairs thermo-
regulation and predisposes patients to hypothermia, which 
reduces the threshold for vasoconstriction and shivering. 
Various pharmacological therapies such as meperidine, 
ketamine and clonidine have been used to prevent shivering, 
because shivering may affect the cardiovascular system and 
induce hypertension and tachycardia, ultimately increasing 
oxygen consumption by 400-500% [1].
    Serotonin (5-hydroxytryptamine [5-HT3]), a biologic amine found 
in the brain and spinal cord, plays a part in neurotransmission; 
studies suggest that the serotonergic system plays a role in 
controlling perioperative shivering [2]. A serotonin 5-HT3 
receptor antagonist inhibits the uptake of serotonin in the 
preoptic anterior hypothalamic region, which influences 
both heat production and heat loss [3], but there has been no 
evidence of this during spinal or epidural anesthesia.
    Ramosetron, a selective serotonin 5-HT3 receptor antagonist, 
is an antiemetic with an indole ring, which is the nucleus of 
serotonin (5-HT) joined by a tetrahydrobenzimidazol radical. 
These components are linked by a carbonyl radical. It has been 
reported that ramosetron exhibits more potent and sustained 
antagonistic activities against 5-HT3 receptors than existing 
5-HT3 receptor antagonist-type antiemetics [4,5]. 
    The aim of our study is to evaluate the efficacy of ramosetron 
on the prevention of shivering during spinal anesthesia.
Materials and Methods
    After informed consent, 52 patients of the American Society 
of Anesthesiologists (ASA) physical status classification I or II 
between the ages of 18 to 62 years who had undergone knee 
arthroscopy under spinal anesthesia were enrolled in this 
study. Patients with obesity (BMI > 30), perioperative fever 
(temperature > 38
oC), hypo- or hyperthyroidism, Parkinson’s 
disease, a requirement for blood transfusion during surgery, 
and medications likely to alter thermoregulation were excluded.
    All patients were randomly allocated to receive 0.9% saline 
(group S, N = 26) or ramosetron 0.3 mg (group R, ramosetron 
(Nasea
®, Astellas, Tokyo, Japan, N = 26). A sample size was 
calculated based on the study by Kelsaka et al., which reported 
the incidence of postanesthetic shivering to be 8% (ondansetron 
group), compared with 36% in the control group. Therefore, 26 
patients were required in each group in order to have a power of 
80% and α = 0.05 [6].
    On arrival in the operating room, 5 ml/kg lactated Ringer’s 
solution warmed to 37
oC was infused over 15 minutes before 
spinal anesthesia. The temperature of the operating room 
during the perioperative period was kept at a set average 
temperature of 24 ± 0.6
oC in all cases. The treatment drugs were 
presented as coded syringes by an anesthesiologist who was 
not involved in the management of the patients. For patients 
allocated in group S, 2 ml 0.9% saline and in group R, 0.3 mg 
ramosetron was intravenously injected immediately before 
intrathecal injection at identical times. Eleven mg of 0.5% 
hyperbaric bupivacaine was injected using a 25-G Quincke 
spinal needle. Spinal anesthesia was performed at the L3-4 
interspace. Shivering was assessed after the completion of the 
subarachnoid injection by observation of the pectoralis major 
muscles for fasciculations of more than 10 seconds duration. 
The presence of intraoperative shivering was noted by a blinded 
observer. If the patient shivered continuously, intravenous 
meperidine 25 mg was administered as a rescue drug. The 
spinal block level was assessed by pinprick and alcohol swab. 
The degree of spinal block was assessed in the intraoperative 
period and also in the recovery unit. Core temperature and the 
presence or absence of shivering were recorded before and 5, 
10, 15, 20, 25, 30, 60, and 120 minutes after spinal anesthesia. 
Core temperatures were measured by tympanic thermometer 
(Infrared Thermometer IRT 4520; accuracy range ± 0.2
oC, Braun, 
USA) and recorded before, after and during spinal anesthesia. 
Systolic and diastolic blood pressures, heart rate, and peripheral 
oxygen saturation were also recorded. Decreases in systolic 
blood pressure more than 20% of the preoperative value were 
treated by crystalloid infusion. If necessary, ephedrine 5 mg was 
administered intravenously. 
    All statistics were analyzed using S-PLUS 8.0 (TIBCO Software 
Inc, CA, USA). Comparison of demographic data and recovery 
characteristics between groups was done by Student’s t-test. 
Comparison of the incidence of shivering between groups was 
done by Fisher’s exact test. The correlation of core temperature 
and anesthetic level was analyzed by Pearson’s correlation test. 
Repeated data on the same participants (changes of block level, 
core temperature, blood pressure and heart rate with time) 
were analyzed by repeated measures ANOVA. P < 0.05 was 
considered statistically significant.
Results
    Demographic data, duration of surgery, duration of anesthesia, 
and volume of infused crystalloid are given in Table 1, which 
shows no significant difference between control group S and 
group R. The range of sensory blockade levels (maximum 
to minimum) was T3-T11 in group S compared to T4-T11 in 
ramosetron group R (Table 2). Two patients in control group 
S showed a maximum block level of T3, while three patients 
in group R showed a maximum block level of T4. The average 
spinal block level in both groups was T6. The mean core 258 www.ekja.org
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temperature during the perioperative period is also shown in 
Table 2. The mean core temperature decreased after spinal 
anesthesia in both groups compared to preoperative values (P 
= 0.01), but there was no significant difference in temperature 
between groups S and R during the intraoperative phase after 
spinal anesthesia. 
    Shivering was observed in 9 patients (34.6%) in group S and 
2 patients (7.7%) in group R (Table 3) (Fisher’s Exact Test; P = 
0.038, odds ratio = 6.14, 95% C.I. = 1.08-65.5). Meperidine was 
given as a rescue drug in 8 patients in group S and 1 patient in 
group R (P = 0.02).
    There was no statistically significant correlation between block 
height and mean core temperature in both group S (Pearson’s 
correlation coefficient, r = 0.14, P = 0.06) and group R (Pearson’s 
correlation coefficient, r = 0.07, P = 0.39).
    There was also no significant difference in systolic blood 
pressure and diastolic blood pressure between the two groups. 
In control group S, 3 patients required ephedrine 5 mg for 
hypotension perioperatively. The peripheral oxygen saturation 
did not fall below 97% in any of the patients during surgery.
    There were no other complications during or after surgery.
Discussion
    In this study, we found that pretreatment with ramosetron is 
an effective way to prevent shivering during spinal anesthesia. 
The incidence of shivering in the ramosetron group was 7.7%, 
which was more than four times less than the incidence of the 
saline group, which was 34.6%.
    It has been reported that shivering develops in up to 40% of 
cases of regional anesthesia [7]. In our study, the incidence of 
shivering in the control group was 34.6%, which is similar to 
the previous report [7]. Shivering is an involuntary, oscillatory 
muscular activity that augments metabolic heat production, 
which is a physiological response to a decrease in core 
temperature. Various pharmacological therapies have been 
used to prevent shivering, because shivering may affect the 
cardiovascular system, causing hypertension and tachycardia, 
ultimately increasing oxygen consumption by 400-500% [1]. 
Clonidine affects noradrenaline through alpha-2 receptors 
located on presynaptic axon terminals in the hypothalamus 
[8]. Meperidine is a very commonly used drug that is used 
prophylactically for shivering. Although the mechanism of 
meperidine is not fully understood, evidence has shown that 
the anti-shivering activity of meperidine may be mediated by its 
kappa opioid receptor activity [1]. Evidence has also suggested 
that the anti-shivering effect of meperidine may be due to 
actions such as monoamine reuptake inhibition, N-methyl-D-
aspartate antagonism or stimulation of alpha-2 adrenoreceptors 
[1]. Ketamine, a competitive NMDA receptor antagonist, 
has been shown to prevent shivering without hemodynamic 
alteration in patients undergoing regional anesthesia; its 
effects are likely due to its influence on the hypothalamus or 
by the beta adrenergic effect of norepinephrine. Ondansetron, 
dolasetron and granisetron, which are all 5-HT3-receptor 
antagonists, have been used effectively to ease postoperative 
shivering. The mechanism for 5-HT3-receptor antagonists 
is still unclear but is thought to be related to inhibition of 
serotonin reuptake on the preoptic anterior hypothalamic 
region. Powell and Buggy [9] reported the amount of shivering 
after general anesthesia in patients in a control group who 
received no drug versus patients who received ondansetron 4 
mg or 8 mg. Shivering occurred in 57% of patients in the control 
group, while 33% and 15% of patients in the ondansetron 4 
mg and 8 mg groups, respectively, experienced shivering, 
showing that administration of 8 mg ondansetron was more 
effective than 4 mg for shivering in patients. In Powell and 
Buggy’s study [9], the effect of ondansetron was independent of 
intraoperative core hypothermia, suggesting that ondansetron 
inhibits thermoregulatory responses by a central mechanism. 
Table 1. Demographic Data
Group S (N = 26) Group R (N = 26)
Age 31 ± 12 45 ± 11
Gender (Female/Male) 6/20 7/19
Weight (kg) 67 ± 8 63 ± 8
Height (cm) 169 ± 8 166 ± 8
Duration of surgery (min) 55 ± 18 45 ± 20
Duration of anesthesia (min) 99 ± 20 85 ± 25
Crystalloid infused (ml) 1,121 ± 271 1,030 ± 276
Values signify the number of patients or the mean ± SD. Group S: sa-
line group, Group R: ramosetron group.
Table 2. Block Level and Core Temperature during Surgery after Spi-
nal Anesthesia
Group S Group R
Block level (maximum)   T6 (T3-T11)   T6 (T4-T11)
Block level (minimum) T10 (T6-T12) T11 (T8-T12)
Core temperature (
oC) 36 ± 0.24 36.5 ± 0.43
Values signify mean ± SD or block level and range of the median for 
that level. Group S: saline group, Group R: ramosetron group.
Table 3. Incidence of Shivering
Group S Group R
Shivering 9 2
No shivering 17 24
Values signify number of patients. Group S: saline group, Group R: 
ramosetron group.259 www.ekja.org
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In regional anesthesia like spinal anesthesia, Kelsaka et al. [6] 
reported the incidence of postanesthetic shivering to be 8% 
(ondansetron 8 mg group) compared to 36% in the control 
group, which was very similar to our results of 7.7% in the 
ramosetron group versus 34.6% in the control group.
    It is well known that ramosetron, a new antagonist of the 
5-hydroxytryptamine type-3 receptor, has more potent and 
longer acting properties for anti-emesis than other 5-HT3-
receptor antagonists such as ondansetron and granisetron. 
Fujii et al. [10] showed that the percentage of patients who 
were emesis free 0-24 hours after anesthesia was 85% with 
granisetron (40 μg/kg) and 90% with ramosetron (6 μg/kg) (P 
= 0.37); the corresponding rate 24-48 hours after anesthesia 
was 70% and 95% (P = 0.003), respectively. Unfortunately, 
there is limited information on the length of time during which 
ramosetron can retain its anti-shivering effect after spinal 
anesthesia. Because we did not directly compare the potency 
and duration of ramosetron to other 5-HT3 receptor antagonists 
in this study, we need further studies to do so.
    There are various risk factors for shivering, such as age, 
level of sensory block, temperature of the operating room 
and temperature of infusion fluid, which is a response to 
hypothermia in regional anesthesia. In this study, there were 
no significant differences in age, temperature of the operating 
room and infusion fluid between groups; therefore, the level 
of sensory block was a major risk factor for shivering. It has 
been shown that spinal anesthesia reduces the threshold 
for vasoconstriction and shivering [1]. In spinal anesthesia, 
reduction in the shivering threshold is proportional to the level 
of spinal blockade. Frank et al. [11] proved that a high level of 
spinal blockade is a significant predictor of core temperature 
during spinal anesthesia. For each increase in block level, the 
core temperature decreases by 0.15
oC [1]. High levels of spinal 
blockade are known to decrease the core temperature threshold 
for shivering. In our study, this correlation was not observed 
in either group. Although it looked as if there was some 
correlation between the spinal block level and the decrease in 
core temperature in the control group (r = 0.14, P = 0.059), there 
was no statistical significance. Moreover, in the study group 
(ramosetron 0.3 mg), a negative correlation (r = 0.07, P = 0.39) 
was shown, which was similar to a previous report of Kelsaka 
et al., which showed that there was a significant correlation 
between the spinal block height and mean rectal temperature 
in the control group. However, this correlation was lost in the 
ondansetron and the meperidine groups [6]. 
    It is unclear why our study did not find a correlation between 
core temperature and block level during spinal anesthesia. 
More clinical studies are needed to compare the efficacy of 
ramosetron to other drugs that can be used to prevent shivering 
in patients undergoing spinal anesthesia.
    In conclusion, we found that pretreatment with ramosetron is 
an effective way to prevent shivering during spinal anesthesia. 
It is common knowledge that meperidine is used as the gold 
standard for the prevention and treatment of perioperative 
shivering. However, its use can be limited because of the risk 
of respiratory depression, sedation, nausea, and vomiting, 
especially when repeated doses are necessary [2]. Therefore, 
we think pretreatment with ramosetron as an alternative to 
meperidine can be a useful way to prevent shivering in spinal 
anesthesia.
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